-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Biotech company NCM today revealed its third oncology candidate drug, NCM438, a new type of antagonized antibody that inhibits white blood cell-related immunoglobulin-like 1 (LAIR1).
LAIR1 is a collagen binding inhibitor expressed on immune cells, which is associated with immunosuppression.
lair1 and collagen are raised in a variety of cancer types, where collagen is produced by active substring cells.
these substring-derived inhibitors were associated with adverse reactions to checkpoint inhibitors.
for such tumors, the formation of laiR1-collagen complexes may act as a substation checkpoint, so inhibiting that substation checkpoint represents a potentially promising new cancer treatment.
NCM438 is designed to inhibit the interaction between LAIR1 and the substring-derived collagen and has the potential to block the substation checkpoint and restore the anti-tumor immune response.
In preclinical studies, NGM438 demonstrated the ability to reprogram collagen-inhibited myelin-inhibited myelin cells as stimulation esopats, and NGM438 has the ability to induce myelin and T-cells to produce inflammatory cytokines and relieve collagen-based T-cell proliferation inhibition.
of collagen-suppressed immune cells may solve key immunotherapy resistance mechanisms.
。
